Results 151 to 160 of about 1,785 (194)

Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function

Antimicrobial Agents and Chemotherapy, 2018
Many antibiotics require dose adjustments in patients with renal impairment and/or in those undergoing hemodialysis. Omadacycline, the first aminomethylcycline antibiotic in late-stage clinical development, displays activity against a broad spectrum of ...
Lynne Garrity-Ryan, Surya Chitra, Stephen Villano   +2 more
exaly   +2 more sources

In Vitro Activity of Omadacycline against Chlamydia pneumoniae [PDF]

Antimicrobial Agents and Chemotherapy, 2019
The activities of omadacycline, azithromycin, doxycycline, moxifloxacin, and levofloxacin were tested against 15 isolates of The minimum inhibitory concentration at which 90% of the isolates of were inhibited by omadacycline was 0.25 μg/ml (range, 0.03 ...
Stephan Kohlhoff
exaly   +2 more sources

Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic [PDF]

Bioorganic and Medicinal Chemistry, 2016
Omadacycline is novel, aminomethyl tetracycline antibiotic being developed for oral and intravenous (IV) administration for the treatment of community-acquired bacterial infections.
Stephen Villano
exaly   +2 more sources

Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects

Antimicrobial Agents and Chemotherapy, 2017
The steady-state concentrations of omadacycline and tigecycline in the plasma, epithelial lining fluid (ELF), and alveolar cells (AC) of 58 healthy adult subjects were obtained. Subjects were administered either omadacycline at 100 mg intravenously (i.v.)
Lynne Garrity-Ryan, Surya Chitra, Keith Rodvold   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Omadacycline in Skin Infections and Pneumonia: A Review of the Evidence

The Journal of Family Practice, 2022
Given the growing prevalence of antibiotic resistance globally, there is an urgent need for new therapy options that are effective and well tolerated for treatment of common infections such as bacterial skin infections and pneumonia. Here, we summarize the findings of 3 phase 3 clinical trials of omadacycline, a novel tetracycline-derived ...
Steve, Vacalis, Stephen, Brunton, Jeff, Gindi   +2 more
openaire   +2 more sources

Omadacycline: First Global Approval

Drugs, 2018
Paratek Pharmaceuticals are developing omadacycline (NUZYRA™), a first-in-class orally active aminomethylcycline antibacterial, as a treatment for various bacterial infections. The drug, which is available in intravenous and oral formulations, has a broad spectrum of antibacterial activity and was recently approved in the USA as a treatment for the ...
Anthony, Markham, Susan J, Keam
openaire   +2 more sources

Omadacycline — The Newest Tetracycline

New England Journal of Medicine, 2019
Omadacycline was the second antibiotic of the tetracycline class to be approved by the Food and Drug Administration (FDA) in 2018.
openaire   +2 more sources

Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics

Clinical Pharmacokinetics, 2019
Omadacycline is a novel aminomethylcycline antibiotic (antibacterial). Omadacycline has had chemical structure modifications at the C9 and C7 positions of the core tetracycline rings that allow stability in the efflux pump and ribosomal protection protein mechanisms of tetracycline resistance. The systemic exposure (i.e., maximum plasma concentrations [
Keith A. Rodvold, Rodrigo M. Burgos, Xing Tan, Manjunath P. Pai   +3 more
openaire   +2 more sources